Gaetan Duport: A New Legislation for Medicines in Europe
Gaetan Duport, Economic and Public Health Committee (CEESP), user representative at Haute Autorité de Santé, reposted from EU Health and Food Safety on LinkedIn:
”A new step forward with the pharma package : a new legislation for medicines in Europe.
A key milestone for better access to treatement.”
Quoting EU Health and Food Safety‘s post:
”Major reform of EU pharmaceutical rules agreed!
We welcome the political agreement reached on the pharma reform last night, which is a crucial step in boosting innovation and investment in the EU’s pharma sector.
The main aim of the new rules is to make sure that medicines in the EU are safe, effective and available to all patients in Europe.
Amongst other things, the rules will:
- Expand access and availability of medicines
- Accelerate medicine supply chains – by cutting red pate for companies and reducing evaluation times for new medicines by the EMA.
- Place the EU at the forefront of pharmaceutical innovation – by offering world-leading incentives for innovative products.
- Allow for speedy market access for generic medicines
- Address medicine shortages
The new rules are complemented by the Critical Medicines’ Act proposal, the recent Life Sciences Strategy and the upcoming Biotech Act.
Check out the factsheet below for more information about the key elements of the reform
For more information.”
Stay updated with Hemostasis Today.
-
Jan 30, 2026, 11:38Aaron Rodriguez Calienes on Intracranial Stenting: Rescue vs First-Line Outcomes
-
Jan 30, 2026, 11:25Ahmed Nasreldein on Sex Disparities in Thrombolysis Delay Among Egyptian Stroke Patients
-
Jan 30, 2026, 11:17Yanki Yarman: My PhD Project Has Been Published in Blood!
-
Jan 30, 2026, 11:08Alexandros Apostolou on Complications Associated with IDU and Thrombophilia
-
Jan 30, 2026, 10:57Peisong Ma on GRK5 Polymorphism Affecting Platelets
-
Jan 30, 2026, 10:47Ashok Yadav Explains Fetal Thrombotic Vasculopathy: FTV
-
Jan 30, 2026, 10:34Saif ur Rahman Compares K2 and K3 EDTA: Key Differences Explained
-
Jan 30, 2026, 10:22Manpreet Gill on Heparin Resistance: When 14 Years of Experience Finally Gets a Plot Twist
-
Jan 30, 2026, 10:14Mohamed Elsaid on The Role of Hyperlipidemia in Thrombogenesis